What The Study Did: This open-label randomized trial compares the effect of remdesivir (5 or 10 days) compared with standard care on clinical status 11 days after treatment initiation among patients with confirmed SARS-CoV-2 infection hospitalized with moderate pneumonia.
Authors: Diana M. Brainard, M.D., of Gilead Sciences in Foster City, California, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
(doi:10.1001/jama.2020.16349)
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Media advisory: The full study and editorial are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https:/
